Impact Factor
3.71
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.18
1,829 total citations
h5-index
50
h5 depth signal
Cited share
69.8%
420 of 602
Total citations
1,829
Citation footprint
Metric signal
3.26
External metric anchor
Self-citation
1.7%
32 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,361
China
866
Italy
561
United Kingdom
465
France
349
Citing Fields of Research
Oncology
1,233
Lung Cancer
565
Breast Cancer
484
Immunology
426
Liver & Colon Cancer
387
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
5,682
Articles tracked across the journal lifetime
Indexed publication set
602
420 cited publications
Last 12 months
293
24.4 publications/month
Open access share
58.0%
170 OA publications in the last year
Leading citing country
United States
1,361 citing publications
Leading citing field
Oncology
1,233 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Feb. 2005-
v1n1, Feb. 2005-
Active Coverage
Research Focus & Classification
Indexed Subjects
Lung Cancer
Oncology
Breast Cancer
Lymphomas
Prostate Cancer
Liver & Colon Cancer
Broad Categories
Neoplasms
Lung Cancer
Lymphomas
Prostate Cancer
Breast Cancer
Immunology
Urology
Digestive Disorders
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/14796694.2026.2751396
Open DOI
AI-driven analysis of genomic alterations in colorectal cancer patients
02
DOI 10.1080/14796694.2026.2750655
Open DOI
First-line osimertinib with or without chemotherapy for EGFR-mutant advanced NSCLC in China: a cost-effectiveness analysis
03
04
DOI 10.1080/14796694.2026.2734063
Open DOI
A plain language summary of the 7-year results from the CROWN study: lorlatinib compared with crizotinib in people with ALK-positive non-small cell lung cancer
A plain language summary of the 7-year results from the CROWN study: lorlatinib compared with crizotinib in people with ALK-positive non-small cell lung cancer. Future Oncology. Ahead of Print. A plain language summary of the 7-year resu...
05
DOI 10.1080/14796694.2026.2732810
Open DOI
Pimicotinib versus placebo in tenosynovial giant cell tumor (TGCT): a plain language summary of the MANEUVER clinical trial
06
07
08
DOI 10.1080/14796694.2026.2720305
Open DOI
Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myeloma
Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myeloma. Future Oncology. Ahead of Print. Plain language summary of t...
09
DOI 10.1080/14796694.2026.2695213
Open DOI
Patient experiences and unmet needs in diagnosis and treatment of metastatic colorectal cancer: results of a US survey
10
DOI 10.1080/14796694.2026.2727260
Open DOI
Plasma ctDNA clinical utility in patients with advanced breast cancer beyond targeted therapy selection
1. Breast cancer is the leading cause of cancer-related mortality among women worlwide with majority of deaths occurring as a result of metastatic progression. Although the introduction of novel th...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.